Objective:

To explore innovative clinical applications and treatment strategies for allo-HSCT in adults and to examine uncommon procedural complications.

Approach:

• Research Topic Overview: The editorial discusses a comprehensive research topic that includes 8 manuscripts: 4 original studies, 2 review articles, and 2 case reports focused on allo-HSCT.
• Personalized Conditioning Protocols: Highlights a trial combining ruxolitinib and decitabine with modified busulfan-cyclophosphamide for high-risk AML/MDS, showing promising survival rates.
• Pre-Transplant Variables: Discusses the impact of pre-transplant spleen volume on outcomes in de novo AML patients, linking it to overall survival and non-relapse mortality.
• Graft Versus Host Disease (GvHD): Reviews treatment strategies for steroid-refractory GvHD, including cyclophosphamide and extracorporeal photopheresis, noting their effectiveness and challenges.
• Thrombotic Microangiopathy (TA-TMA): Explores the etiology and treatment options for TA-TMA, including novel therapies like iptacopan for refractory cases.
• Platelet Transfusion Refractoriness (PTR): Analyzes early PTR in aplastic anemia patients, indicating it is infrequent and does not significantly affect post-engraftment outcomes.

Key Findings:

• The combination of ruxolitinib and decitabine with mBu/Cy shows a 2-year overall survival probability of 70.3% in high-risk AML/MDS patients.
• Pre-transplant spleen volume is an independent prognostic factor affecting outcomes after allo-HSCT.
• Cyclophosphamide is effective for salvage treatment of steroid-refractory hepatic acute GvHD with a 70% overall response rate.
• Extracorporeal photopheresis is effective for steroid-refractory GvHD but requires multiple sessions.
• Iptacopan may provide a new treatment option for refractory TA-TMA.
• Early PTR is infrequent and does not significantly impact outcomes after successful engraftment.

Interpretation:

The editorial emphasizes the importance of innovative treatment strategies and the need for ongoing research to address complications associated with allo-HSCT.

Limitations:

• The editorial does not provide extensive data on the long-term outcomes of the discussed treatment strategies.
• Some findings are based on retrospective analyses, which may limit the generalizability of the results.

Conclusion:

The editorial highlights advancements in allo-HSCT treatment strategies and the need for further research into uncommon complications.